Baidu
map

消化

订阅

MedSci主页 / 所有栏目 / 消化

JCC：IL-6缺失会加剧IL-10缺乏小鼠的结肠炎并诱发全身性炎症

2019-11-09 不详 MedSci原创

(IBD)Interleukin10(IL-10)Interleukin6(IL-6)
关注

白介素6（IL-6）或其受体目前是炎症性肠病（IBD）靶向生物治疗的候选药物。因此，必须全面了解阻断IL-6的后果。本项研究旨在通过评估IL-6缺失对IL-10缺陷小鼠（IL-10 -/-）自发性结肠炎的影响来预测相关后果。

背景和目标
白介素6（IL-6）或其受体目前是炎症性肠病（IBD）靶向生物治疗的候选药物。因此，必须全面了解阻断IL-6的后果。本项研究旨在通过评估IL-6缺失对IL-10缺陷小鼠（IL-10 -/-）自发性结肠炎的影响来预测相关后果。

方法
研究人员构建了IL-6 / IL-10双缺陷小鼠（IL-6 -/- / IL-10 -/-），并与WT和IL-10 -/-小鼠相比分析结肠粘膜的肠道炎症，一般表型和分子/生化的变化。

结果
出乎意料的是，在肠道炎症和全身炎症的比较中，IL-6 -/- / IL-10 -/-小鼠表现出比IL-10 -/ -小鼠更明显的肠道炎症和更早的疾病发作，白细胞增多，中性粒细胞增多和单核细胞增多。IL-6 -/- / IL-10 -/-小鼠表现出多种细胞因子（IL-1β，IL-4，IL-12，TNFα）和趋化因子（MCP-1和MIG）的升高。FOXP3和TGF-β，对于调节性T（Treg细胞）细胞分化的两个关键因素，在结肠黏膜中均显着下调。当IL-6 -/- / IL-10 -/-小鼠的结肠粘膜中iNOS上调时，CTLA-4减少。

结论
在IL-10 -/-小鼠中，完全的IL-6阻断至少部分通过抑制Treg / CTLA-4并促进IL-1β/ Th2途径显着加重了肠道炎症。

原始出处：

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1273785, encodeId=74da12e37855f, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Sun Nov 10 15:41:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508256, encodeId=bc691508256d1, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sun Nov 10 15:41:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587649, encodeId=bbe6158e649f5, content=<a href='/topic/show?id=a6f6962576' target=_blank style='color:#2F92EE;'>#IL-10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9625, encryptionId=a6f6962576, topicName=IL-10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8cd17536453, createdName=xiaoyeshuang, createdTime=Sun Nov 10 15:41:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374954, encodeId=58273e495401, content=谢谢了，学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Nov 09 07:43:01 CST 2019, time=2019-11-09, status=1, ipAttribution=)]
    2019-11-10 kzlchina

    #IL-6#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1273785, encodeId=74da12e37855f, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Sun Nov 10 15:41:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508256, encodeId=bc691508256d1, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sun Nov 10 15:41:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587649, encodeId=bbe6158e649f5, content=<a href='/topic/show?id=a6f6962576' target=_blank style='color:#2F92EE;'>#IL-10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9625, encryptionId=a6f6962576, topicName=IL-10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8cd17536453, createdName=xiaoyeshuang, createdTime=Sun Nov 10 15:41:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374954, encodeId=58273e495401, content=谢谢了，学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Nov 09 07:43:01 CST 2019, time=2019-11-09, status=1, ipAttribution=)]
    2019-11-10 jjjiang0202

    #IL-1#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1273785, encodeId=74da12e37855f, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Sun Nov 10 15:41:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508256, encodeId=bc691508256d1, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sun Nov 10 15:41:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587649, encodeId=bbe6158e649f5, content=<a href='/topic/show?id=a6f6962576' target=_blank style='color:#2F92EE;'>#IL-10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9625, encryptionId=a6f6962576, topicName=IL-10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8cd17536453, createdName=xiaoyeshuang, createdTime=Sun Nov 10 15:41:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374954, encodeId=58273e495401, content=谢谢了，学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Nov 09 07:43:01 CST 2019, time=2019-11-09, status=1, ipAttribution=)]
    2019-11-10 xiaoyeshuang

    #IL-10#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1273785, encodeId=74da12e37855f, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Sun Nov 10 15:41:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508256, encodeId=bc691508256d1, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sun Nov 10 15:41:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587649, encodeId=bbe6158e649f5, content=<a href='/topic/show?id=a6f6962576' target=_blank style='color:#2F92EE;'>#IL-10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9625, encryptionId=a6f6962576, topicName=IL-10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8cd17536453, createdName=xiaoyeshuang, createdTime=Sun Nov 10 15:41:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374954, encodeId=58273e495401, content=谢谢了，学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Nov 09 07:43:01 CST 2019, time=2019-11-09, status=1, ipAttribution=)]
    2019-11-09 txqjm

    谢谢了，学习

    0

相关资讯

IBD： 荷尔蒙波动对炎症性肠病症状严重度的影响的横断面队列研究

许多炎症性肠病（IBD）妇女报告在月经，怀孕和使用激素避孕药期间与疾病症状的改变与体内激素变化相关。我们的目标是在激素变异期间鉴定女性IBD症状炎症活动程度的波动。

DDS： 结肠炎模型小鼠中循环免疫活性细胞的增加会导致肺对细菌内毒素反应的增强

与一般人群相比，患有炎性肠病的患者具有更高的气道高反应性发生率。因此本项研究旨在研究对结肠小鼠中细菌内毒素与肺炎症反应之间的关系。

IBD：粪便气味可以区分小儿肠易激综合征与炎症性肠病

小儿肠易激综合征（IBS）和功能性腹痛的诊断检查通常需要用于区分炎症性肠病（IBD）的侵入性测试，这会给患者带来很大的负担，因此需要开发用于IBS和IBD的非侵入性诊断生物标志物。一些研究表明IBS / FAP中的微生物群改变被认为是可以有粪便挥发性有机化合物（VOC）反映出来。本研究的目的是评估是否可以通过粪便VOC将儿童IBS与IBD和健康对照区分开来。

Baidu
map
Baidu
map
Baidu
map